Leiden, Netherlands-based healthtech company, RespiQ received EUR 4 million grant. The company announced the funding on November 20, 2023. European Innovation Council (EIC) provided the financing the company. The grant is part of the EIC Pathfinder Challenge: “Towards the healthcare continuum.” The initiative seeks to support innovative technologies facilitating the transition from episodic to continuous patient care across Europe.
RespiQ will receive EUR 4 million grant over the next three and a half years alongside a distinguished international consortium of renowned academic institutions and medical research organisations. It includes King’s Centre for Lung Health, School of Immunology and Microbial Sciences at King’s College London, the National eHealth Living Lab within the Leiden University Medical Centre (LUMC), the Norwegian research organisation Sintef, and the Portuguese technical consulting and research company, uRoboptics.
Purpose of financing for RespiQ
The recent financing further fuels the momentum of RespiQ’s mission to enhance the well-being of COPD patients with their groundbreaking breath diagnostics technology.
With the latest financing, the company seeks to accelerate the development and miniaturization of RespiQ’s cutting-edge breath diagnostics technology. The technology enhancies non-invasive remote patient monitoring.
What the company’s official has to add
Mira Gleisberg, CEO of RespiQ, said, “Receiving the EIC Pathfinder grant marks a significant milestone for our company and consortium, as it enables us to accelerate the development of our cutting-edge breath diagnostics device, bringing hope to thousands of COPD patients struggling to monitor their disease.”
What the investors have to comment
Professor Mona Bafadhel, Chair of Respiratory Medicine and Director of the King’s Centre for Lung Health at King’s College London, further added, “The impact of this funding will be potentially game-changing. Ways to diagnose onset of deterioration in COPD are urgently warranted. With a non-invasive test like a breath test, this could mean that in the future patients living with COPD will be able to safely monitor their condition without the need for a trip to hospital. As the clinical partner for this project, we look forward to the advancements this funding will allow our research to achieve for COPD patients in the future.”
RJ Schuurs, Partner at Antler, said, “We are delighted to have supported RespiQ from day zero of their growth journey and this prestigious funding grant is testament to their long-term growth potential. This is an outstanding founding team building a technology that could improve the lives of thousands of people around the world. We are very excited to see what RespiQ and their consortium partners can deliver in the coming years.”
About the company
Mira Gleisberg and Vitalii Vorkov launched the company. The idea of RespiQ came into existence from a founder residency in Amsterdam run by Antler in 2019.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
